Effect of Candesarutan and Piogritazon in diabetic patients with hypertension

Effect of Candesarutan and Piogritazon in diabetic patients with hypertension - Effect of Candesarutan and Piogritazon in diabetic patients with hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010142

Enrollment

Registered

2013-03-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with hypertension

Interventions

24-week treatment of high dose Candesarutan and Piogritazon in hypertension.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes and hypertension(Age 40-80 years). Patients who has not been taking Piogritazon. Informed consent obtained.

Exclusion criteria

Exclusion criteria: Contraindicated of Piogritazon and Candesartan. Informed consent can not be obtained. Patients judged to be unsuitable

Design outcomes

Primary

Measure	Time frame
Evaluation of marker for inflammation in diabetic patients with hypertension	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026